Implications of the FDA Approval of Subcutaneous Amivantamab in EGFR+ NSCLC

Christine Lovly, MD, PhD, and Matthew Lee, MD, discuss the clinical implications of the FDA approval of amivantamab and hyaluronidase-lpuj (Rybrevant Faspro; subcutaneous amivantamab) in EGFR-mutated non–small cell lung cancer. Lovly highlights how this formulation may improve patient convenience and reduce administration-related burden compared with intravenous delivery. Lee notes that these changes could influence treatment selection by improving the overall risk–benefit profile and patient experience.